A Sharply Defined Pattern of Central Retinal Thinning
A hand-woven mat can develop one small section where the fibres have completely unravelled down to bare thread, while every other part of the weave stays tight and intact around it. Under retinal examination, central areolar choroidal dystrophy produces a broadly similar look — a well-outlined zone of atrophy positioned directly beneath the macula, while the retina and choroid nearby stay mostly undisturbed. That unusually crisp, well-defined edge is generally the very first thing a specialist notices.
Most Rwandan patients come to us with this diagnosis already in their thirties or forties, often because an unrelated eye check revealed a pale, unusually well-bordered patch that a sharp-eyed local ophthalmologist correctly identified as out of place for ordinary ageing at that point in life.
Nobody usually catches the exact moment it started — it only becomes obvious looking backward. Reading that used to be effortless slowly turns effortful over a year or two. Someone might notice tilting their head slightly to shift a face out of dead centre and into clearer view. As the patch settles into central vision, sharply bordered and unmistakable, everything else keeps working normally — crossing a room, finding a doorway, moving through a crowd. Only that narrow central window is ever touched, and vision in dim light stays completely untouched throughout.
Most confirmed cases point back to the PRPH2 gene, which under normal conditions builds a structural protein photoreceptor cells rely on to keep their shape and function properly. When it fails, three tightly stacked layers beneath the macula — the choriocapillaris, the retinal pigment epithelium, and the photoreceptors above them — break down together, though strictly within that one confined patch rather than beyond it. Families typically see it inherited as a dominant trait, resurfacing generation after generation.
The border of the atrophic patch is what catches attention first — unusually crisp, almost machine-cut, and fundus autofluorescence is the best available tool for mapping exactly where that edge sits. OCT reveals how much photoreceptor tissue is holding on at the margin, often the single most useful detail for planning what comes next, while a largely normal ERG offers reassurance that the process has genuinely stayed contained. A PRPH2 genetic test rounds off the picture.
Rather than sticking to a rigid calendar, care follows however fast the atrophic zone is actually spreading, tracked through repeated imaging over time instead of judged from one appointment. Patients who qualify are considered for regenerative stem cell therapy aimed at protecting retina still working at the edge of the affected zone, and as the central blind spot takes clearer shape, we build practical low-vision strategies tailored to that individual pattern.
Not remotely — that finding actually matches what we'd expect, rather than raising any doubt. Since the disease is limited to a small central patch and never touches the rod cells that handle night vision, seeing in low light usually stays dependable even as close-up tasks get harder.
No, there's no set stopping point — a portion of patients barely shift over ten years, while others show clearer movement within a much shorter span. That's precisely why repeated imaging over time matters more than trying to guess a single fixed growth rate.
They can look strikingly alike side by side, but the cause and the timing are quite different — yours from an inherited gene fault showing up decades early, hers from age-related change building up much later in life. What distinguishes the two comes down to genetic testing paired with the age things first began.
Unlikely for most patients — day-to-day movement and orientation generally hold steady, because the disease stays boxed into one central patch rather than touching the wider field that guides how we get around.